CN110724148B - 对氯苯基取代含吡唑结构的螺[吲唑-吡唑啉]衍生物及其制备方法与应用 - Google Patents
对氯苯基取代含吡唑结构的螺[吲唑-吡唑啉]衍生物及其制备方法与应用 Download PDFInfo
- Publication number
- CN110724148B CN110724148B CN201911068676.3A CN201911068676A CN110724148B CN 110724148 B CN110724148 B CN 110724148B CN 201911068676 A CN201911068676 A CN 201911068676A CN 110724148 B CN110724148 B CN 110724148B
- Authority
- CN
- China
- Prior art keywords
- phenyl
- indazole
- methyl
- pyrazole
- pyrazoline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 125000003003 spiro group Chemical group 0.000 title claims abstract description 32
- 125000003226 pyrazolyl group Chemical group 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title abstract description 14
- MXOAEAUPQDYUQM-UHFFFAOYSA-N chlorphenesin Chemical group OCC(O)COC1=CC=C(Cl)C=C1 MXOAEAUPQDYUQM-UHFFFAOYSA-N 0.000 title description 2
- -1 1,2, 4-triazole-1-yl Chemical group 0.000 claims abstract description 32
- IDBOAVAEGRJRIZ-UHFFFAOYSA-N methylidenehydrazine Chemical compound NN=C IDBOAVAEGRJRIZ-UHFFFAOYSA-N 0.000 claims abstract description 17
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 14
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 12
- 150000002576 ketones Chemical class 0.000 claims abstract description 6
- 230000002194 synthesizing effect Effects 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 39
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 27
- 238000003756 stirring Methods 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 17
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 10
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 238000009835 boiling Methods 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 239000000047 product Substances 0.000 claims description 9
- 238000010992 reflux Methods 0.000 claims description 9
- 239000007787 solid Substances 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 239000003208 petroleum Substances 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 7
- 238000000967 suction filtration Methods 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 claims description 6
- 229940067157 phenylhydrazine Drugs 0.000 claims description 6
- 239000002244 precipitate Substances 0.000 claims description 6
- IXZDIALLLMRYOU-UHFFFAOYSA-N tert-butyl hypochlorite Chemical compound CC(C)(C)OCl IXZDIALLLMRYOU-UHFFFAOYSA-N 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000011259 mixed solution Substances 0.000 claims description 4
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims description 3
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 claims description 3
- DKZPJLZXLKAMDO-UHFFFAOYSA-N 5-chloro-3-methyl-1-phenylpyrazole-4-carbaldehyde Chemical compound ClC1=C(C=O)C(C)=NN1C1=CC=CC=C1 DKZPJLZXLKAMDO-UHFFFAOYSA-N 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- 239000012153 distilled water Substances 0.000 claims description 3
- 239000003480 eluent Substances 0.000 claims description 3
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 3
- 239000012065 filter cake Substances 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 239000005457 ice water Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 238000003760 magnetic stirring Methods 0.000 claims description 3
- 230000001376 precipitating effect Effects 0.000 claims description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 3
- 238000002390 rotary evaporation Methods 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 238000010898 silica gel chromatography Methods 0.000 claims description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 3
- 238000009210 therapy by ultrasound Methods 0.000 claims description 3
- 238000002604 ultrasonography Methods 0.000 claims description 3
- 238000001291 vacuum drying Methods 0.000 claims description 3
- 238000001704 evaporation Methods 0.000 claims description 2
- 239000012467 final product Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- SQDFHQJTAWCFIB-UHFFFAOYSA-N n-methylidenehydroxylamine Chemical compound ON=C SQDFHQJTAWCFIB-UHFFFAOYSA-N 0.000 claims description 2
- 238000003828 vacuum filtration Methods 0.000 claims description 2
- UOQXIWFBQSVDPP-UHFFFAOYSA-N 4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1 UOQXIWFBQSVDPP-UHFFFAOYSA-N 0.000 claims 1
- BJSZPAVHYNGZDX-UHFFFAOYSA-N 5-[(4-fluorophenyl)methylidene]-1-phenyl-6,7-dihydroindazol-4-one Chemical compound FC1=CC=C(C=C2C(C=3C=NN(C=3CC2)C2=CC=CC=C2)=O)C=C1 BJSZPAVHYNGZDX-UHFFFAOYSA-N 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 abstract description 18
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical group C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 4
- YYDYZZXPYOLBON-UHFFFAOYSA-N 3-methyl-1-phenyl-5-(1H-1,2,4-triazol-5-yl)pyrazole-4-carbaldehyde Chemical compound CC1=NN(C(=C1C=O)C1=NNC=N1)C1=CC=CC=C1 YYDYZZXPYOLBON-UHFFFAOYSA-N 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 3
- HJSZBQAOFLABMN-UHFFFAOYSA-N N1N=CC2=CC=CC=C12.N1NC=CC1 Chemical compound N1N=CC2=CC=CC=C12.N1NC=CC1 HJSZBQAOFLABMN-UHFFFAOYSA-N 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 18
- 150000001875 compounds Chemical class 0.000 description 18
- QAFDRLLAGZSJLN-UHFFFAOYSA-N 5-[(4-chlorophenyl)methylidene]-1-phenyl-6,7-dihydroindazol-4-one Chemical compound ClC1=CC=C(C=C2C(C=3C=NN(C=3CC2)C2=CC=CC=C2)=O)C=C1 QAFDRLLAGZSJLN-UHFFFAOYSA-N 0.000 description 15
- 210000004881 tumor cell Anatomy 0.000 description 9
- 229940125782 compound 2 Drugs 0.000 description 8
- 229940126214 compound 3 Drugs 0.000 description 8
- 229940125898 compound 5 Drugs 0.000 description 6
- 238000006736 Huisgen cycloaddition reaction Methods 0.000 description 5
- 125000003626 1,2,4-triazol-1-yl group Chemical group [*]N1N=C([H])N=C1[H] 0.000 description 4
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 4
- 229940125904 compound 1 Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 3
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 201000005249 lung adenocarcinoma Diseases 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- AVPYQKSLYISFPO-UHFFFAOYSA-N 4-chlorobenzaldehyde Chemical compound ClC1=CC=C(C=O)C=C1 AVPYQKSLYISFPO-UHFFFAOYSA-N 0.000 description 2
- GLFSWUCOPYLJBI-UHFFFAOYSA-N C1CC=NO1.C1=CC=CN2C=CC=C21 Chemical compound C1CC=NO1.C1=CC=CN2C=CC=C21 GLFSWUCOPYLJBI-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 150000002391 heterocyclic compounds Chemical class 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 150000003217 pyrazoles Chemical class 0.000 description 2
- PSXCLWPFIRHOJO-UHFFFAOYSA-N 1-phenyl-6,7-dihydro-5h-indazol-4-one Chemical compound O=C1CCCC2=C1C=NN2C1=CC=CC=C1 PSXCLWPFIRHOJO-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- NPHULPIAPWNOOH-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-(2,3-dihydroindol-1-ylmethyl)pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)CN1CCC2=CC=CC=C12 NPHULPIAPWNOOH-UHFFFAOYSA-N 0.000 description 1
- WWSJZGAPAVMETJ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-ethoxypyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)OCC WWSJZGAPAVMETJ-UHFFFAOYSA-N 0.000 description 1
- LPZOCVVDSHQFST-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-ethylpyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)CC LPZOCVVDSHQFST-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- FSUFOMZXMFNBIM-UHFFFAOYSA-N [3-methyl-1-phenyl-5-(1,2,4-triazol-1-yl)pyrazol-4-yl]methylidenehydrazine Chemical compound C1(=CC=CC=C1)N1N=C(C(=C1N1N=CN=C1)C=NN)C FSUFOMZXMFNBIM-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Chemical compound Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
加入次数 | 产率 | |
实施例1 | 3 | 92% |
实施例10 | 1 | 57% |
实施例11 | 2 | 85% |
实施例12 | 4 | 87% |
实施例13 | 5 | 84% |
冰盐浴的温度 | 产率 | |
实施例1 | -12 | 92% |
实施例14 | 0 | 0% |
实施例15 | -5 | 37% |
实施例16 | -8 | 66% |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911068676.3A CN110724148B (zh) | 2019-11-05 | 2019-11-05 | 对氯苯基取代含吡唑结构的螺[吲唑-吡唑啉]衍生物及其制备方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911068676.3A CN110724148B (zh) | 2019-11-05 | 2019-11-05 | 对氯苯基取代含吡唑结构的螺[吲唑-吡唑啉]衍生物及其制备方法与应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110724148A CN110724148A (zh) | 2020-01-24 |
CN110724148B true CN110724148B (zh) | 2021-02-09 |
Family
ID=69223821
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911068676.3A Active CN110724148B (zh) | 2019-11-05 | 2019-11-05 | 对氯苯基取代含吡唑结构的螺[吲唑-吡唑啉]衍生物及其制备方法与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110724148B (zh) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108752365B (zh) * | 2018-06-14 | 2019-10-18 | 绍兴文理学院 | 一种含吡唑结构的螺[吲哚嗪-异噁唑啉]衍生物及其制备方法与应用 |
-
2019
- 2019-11-05 CN CN201911068676.3A patent/CN110724148B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN110724148A (zh) | 2020-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110642864B (zh) | 含吡唑结构的螺[吲唑-吡唑啉]衍生物及制备方法与应用 | |
CN110128444B (zh) | 对硝基苯基取代含色酮结构的螺[吲唑-异噁唑]衍生物及制备方法与应用 | |
CN110759920A (zh) | 对甲氧基苯基取代含吡唑结构的螺[吲唑-吡唑啉]衍生物及其制备方法与应用 | |
CN110724148B (zh) | 对氯苯基取代含吡唑结构的螺[吲唑-吡唑啉]衍生物及其制备方法与应用 | |
CN110790769B (zh) | 对甲基苯基取代含吡唑结构的螺[吲唑-吡唑啉]衍生物及其制备方法与应用 | |
CN110655522B (zh) | 邻氯苯基取代含吡唑结构的螺[吲唑-吡唑啉]衍生物及其制备方法与应用 | |
CN110746431B (zh) | 对甲巯基苯基取代含吡唑结构的螺[吲唑-吡唑啉]衍生物及其制备方法与应用 | |
CN110734442B (zh) | 3,4,5-三甲氧基苯基取代含吡唑结构的螺[吲唑-吡唑啉]衍生物及制备方法与应用 | |
CN110183467B (zh) | 对甲氧基苯基取代含色酮结构的螺[吲唑-异噁唑]衍生物及制备方法与应用 | |
CN108623604B (zh) | 一种d-苯丙氨酸取代马来酰亚胺衍生物及其制备方法与应用 | |
CN110759921A (zh) | 对氟苯基取代含吡唑结构的螺[吲唑-吡唑啉]衍生物及其制备方法与应用 | |
CN112645957A (zh) | 一种含哒嗪酮结构的螺吡唑-吡咯里嗪衍生物及其制备方法与应用 | |
CN110128445B (zh) | 对氯苯基取代含色酮结构的螺[吲唑-异噁唑]衍生物及制备方法与应用 | |
CN110143971B (zh) | 甲巯基苯基取代含色酮结构的螺[吲唑-异噁唑]衍生物及制备方法与应用 | |
CN110256462B (zh) | 对氟苯基取代含色酮结构的螺[吲唑-异噁唑]衍生物及制备方法与应用 | |
CN108690028B (zh) | 一种l-缬氨酸取代马来酰亚胺衍生物及其制备方法与应用 | |
CN108623603B (zh) | 一种l-亮氨酸取代马来酰亚胺衍生物及其制备方法与应用 | |
CN110128447B (zh) | 对甲基苯基取代含色酮结构的螺[吲唑-异噁唑]衍生物及制备方法与应用 | |
CN110128446B (zh) | 3,4,5-三甲氧基苯基取代含色酮结构的螺[吲唑-异噁唑]衍生物及制备方法与应用 | |
CN108707153B (zh) | 一种d-缬氨酸取代马来酰亚胺衍生物及其制备方法与应用 | |
CN108676008B (zh) | 一种d-亮氨酸取代马来酰亚胺衍生物及其制备方法与应用 | |
CN108727383B (zh) | 一种l-苯丙氨酸取代马来酰亚胺衍生物及其制备方法与应用 | |
CN110156812B (zh) | 含色酮结构的螺[吲唑-异噁唑]衍生物及制备方法与应用 | |
CN109180675B (zh) | 一种对甲氧基取代含哒嗪酮结构的螺[吲哚嗪-吡唑啉]衍生物及其制备方法与应用 | |
CN111909230B (zh) | 氯取代阿拉伯糖三氮唑结构螺异噁唑-吡咯里嗪衍生物及其制备方法与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20211117 Address after: 250000 1422, building n, Hengda City, No. 58, Gongye North Road, Licheng District, Jinan City, Shandong Province Patentee after: Jinan Weiyang Technology Co.,Ltd. Address before: 312000 No. 508 West Ring Road, Zhejiang, Shaoxing Patentee before: SHAOXING University |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220509 Address after: 211899 floor 3, building 02, life science and technology Island, No. 11, Yaogu Avenue, Jiangbei new area, Nanjing, Jiangsu Patentee after: Xunuo Pharmaceutical (Nanjing) Co.,Ltd. Address before: 250000 1422, building n, Hengda City, No. 58, Gongye North Road, Licheng District, Jinan City, Shandong Province Patentee before: Jinan Weiyang Technology Co.,Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Preparation and application of spiro [indole pyrazoline] derivatives containing pyrazole structures substituted with chlorophenyl groups Granted publication date: 20210209 Pledgee: Bank of Nanjing Jiangbei District branch of Limited by Share Ltd. Pledgor: Xunuo Pharmaceutical (Nanjing) Co.,Ltd. Registration number: Y2024980022886 |